Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence
Abstract Nebulised unfractionated heparin (UFH) has a strong scientific and biological rationale and warrants urgent investigation of its therapeutic potential, for COVID-19-induced acute respiratory distress syndrome (ARDS). COVID-19 ARDS displays the typical features of diffuse alveolar damage wit...
Main Authors: | Frank M. P. van Haren, Clive Page, John G. Laffey, Antonio Artigas, Marta Camprubi-Rimblas, Quentin Nunes, Roger Smith, Janis Shute, Mary Carroll, Julia Tree, Miles Carroll, Dave Singh, Tom Wilkinson, Barry Dixon |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | Critical Care |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13054-020-03148-2 |
Similar Items
-
Therapeutic inefficacy of protocol driven intravenous unfractionated heparin infusion in the current era
by: Kayla Torppey, et al.
Published: (2023-10-01) -
Inactivation of Heparin by Cationically Modified Chitosan
by: Barbara Lorkowska-Zawicka, et al.
Published: (2014-06-01) -
Does ‘heparin-induced thrombocytopenia’ hit our minds?
by: Arun R. Thangavel, et al.
Published: (2016-08-01) -
Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease
by: Janis Kay Shute
Published: (2023-04-01) -
Incidence of anti-heparin/platelet factor 4 antibodies and heparin-induced thrombocytopenia in medical patients
by: Mahmut Yüksel, et al.
Published: (2009-12-01)